[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008046082A3 - Use of heterocyclic compounds as therapeutic agents - Google Patents

Use of heterocyclic compounds as therapeutic agents Download PDF

Info

Publication number
WO2008046082A3
WO2008046082A3 PCT/US2007/081318 US2007081318W WO2008046082A3 WO 2008046082 A3 WO2008046082 A3 WO 2008046082A3 US 2007081318 W US2007081318 W US 2007081318W WO 2008046082 A3 WO2008046082 A3 WO 2008046082A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compounds
therapeutic agents
pruritis
hypercholesterolemia
cancer
Prior art date
Application number
PCT/US2007/081318
Other languages
French (fr)
Other versions
WO2008046082A2 (en
Inventor
Mikhail Chafeev
Sultan Chowdhury
Robert Fraser
Jianmin Fu
Rajender Kamboj
Shifeng Liu
Vandna Raina
Bagherzadeh Mehran Seid
Jianyu Sun
Serguei Sviridov
Original Assignee
Xenon Pharmaceuticals Inc
Mikhail Chafeev
Sultan Chowdhury
Robert Fraser
Jianmin Fu
Rajender Kamboj
Shifeng Liu
Vandna Raina
Bagherzadeh Mehran Seid
Jianyu Sun
Serguei Sviridov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Mikhail Chafeev, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Rajender Kamboj, Shifeng Liu, Vandna Raina, Bagherzadeh Mehran Seid, Jianyu Sun, Serguei Sviridov filed Critical Xenon Pharmaceuticals Inc
Publication of WO2008046082A2 publication Critical patent/WO2008046082A2/en
Publication of WO2008046082A3 publication Critical patent/WO2008046082A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to the use of heterocyclic compounds for the treatment and/or prevention of diseases or conditions such as hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.
PCT/US2007/081318 2006-10-12 2007-10-12 Use of heterocyclic compounds as therapeutic agents WO2008046082A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85123606P 2006-10-12 2006-10-12
US60/851,236 2006-10-12

Publications (2)

Publication Number Publication Date
WO2008046082A2 WO2008046082A2 (en) 2008-04-17
WO2008046082A3 true WO2008046082A3 (en) 2008-06-19

Family

ID=39283677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081318 WO2008046082A2 (en) 2006-10-12 2007-10-12 Use of heterocyclic compounds as therapeutic agents

Country Status (1)

Country Link
WO (1) WO2008046082A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (en) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc ESPIRO-OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
AR053710A1 (en) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc SPIROHETEROCICLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
CL2007002950A1 (en) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc USE OF COMPOUNDS DERIVED FROM ESPIRO-OXINDOL IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER
PL2283006T3 (en) 2008-04-24 2015-08-31 F2G Ltd Pyrrole antifungal agents
DK2350090T3 (en) 2008-10-17 2015-09-07 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
MY179342A (en) 2009-10-14 2020-11-04 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US10709714B2 (en) 2013-11-22 2020-07-14 Clifton Life Sciences LLC Gastrin antagonists for treatment and prevention of osteoporosis
PL3221308T3 (en) 2014-11-21 2019-03-29 F2G Limited Antifungal agents
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110654A1 (en) * 2005-04-11 2006-10-19 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110654A1 (en) * 2005-04-11 2006-10-19 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGER T ET AL: "MEDICINAL CHEMISTRY OF NEURONAL VOLTAGE-GATED SODIUM CHANNEL BLOCKERS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 2, 18 January 2001 (2001-01-18), pages 115 - 137, XP009049196, ISSN: 0022-2623 *
FRASER SCOTT P ET AL: "Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5381 - 5389, XP002415107, ISSN: 1078-0432 *
SMITH P ET AL: "Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 423, no. 1, 13 February 1998 (1998-02-13), pages 19 - 24, XP004261853, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2008046082A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008046083A3 (en) Use of oxindole compounds as therapeutic agents
WO2008046082A3 (en) Use of heterocyclic compounds as therapeutic agents
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
MX2009006704A (en) New compounds.
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2006099379A3 (en) Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2007098507A3 (en) Compositions and methods for inhibition of the jak pathway
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007117607A3 (en) Quinazolines for pdk1 inhibition
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2006017384A3 (en) Indazoles useful in treating cardiovascular diseases
WO2008024977A3 (en) Isoquinoline, quinazoline and phthalazine derivatives
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007108947A3 (en) Nitrofuran compounds for the treatment of cancer and angiogenesis

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854024

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07854024

Country of ref document: EP

Kind code of ref document: A2